Equillium Inc EQ

$1.41 -0.13 (-8.44%)

Valuation

Market cap
97,648,000
Revenue TTM
$0
Net income TTM
$-22,400,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
934,700
Avg volume
571,772
Day's range
$1.38 – $1.60
Shares out
63,408,000
Stochastic %K
6%
Beta
1.93
Analysts
Strong Sell
Price target
$8.60

Price

Company profile

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral del...

Show more

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 240 1200
Website
https://www.equilliumbio.com
Address
2223 Avenida De La Playa, Suite 105, La Jolla, United States

Latest news

Stocktwits

Orlandotrader Sep 22, 7:52 PM
$EQ What’s with the Crazy Volume?? Hedge funds?
0 replies
Orlandotrader Sep 17, 8:11 PM
$EQ EQ don’t look GQ.
0 replies
LordFawkwadReturns Sep 15, 4:20 PM
$EQ Pure manipulation.
1 replies
BanditQ Sep 15, 3:34 PM
$EQ tempting to get back in lol 🤣
1 replies
ADelightfulman Sep 14, 7:09 PM
$EQ added
0 replies
Publicola29 Sep 10, 6:56 PM
$EQ Results EQ504 induced robust, dose-dependent AhR activation, and was ∼10-fold more potent than the clinically validated AhR agonist obefazimod in the EROD assay. Functionally, EQ504 significantly accelerated epithelial wound closure in scratch assays, whereas obefazimod showed minimal or no effect under equivalent conditions. At matched concentrations, EQ504 increased expression of the IL-22 receptor subunit IL22RA and reduced expression of the pore-forming tight junction protein claudin-2 (CLDN2), consistent with enhanced epithelial repair, which were not observed with obefazimod.
0 replies
Publicola29 Sep 10, 6:20 PM
$EQ Preclinical and in vitro studies indicate that EQ504 demonstrates superior epithelial repair and higher aryl hydrocarbon receptor (AhR) potency compared to obefazimod, though obefazimod is further along in clinical development. [1] (https://academic.oup.com/jimmunol/article-abstract/215/Supplement_1/vkag141.1641/8744890), [2] (https://www.encodelp.com/coverage-universe/eq/)Potency and Epithelial RepairHigher Potency: In EROD assays, EQ504 showed roughly 10-fold greater potency in activating AhR than obefazimod. [1] (https://academic.oup.com/jimmunol/article-abstract/215/Supplement_1/vkag141.1641/8744890)Wound Healing: EQ504 significantly accelerated human intestinal epithelial cell wound closure in scratch assays, while obefazimod showed minimal or no effect. [1] (https://academic.oup.com/jimmunol/article-abstract/215/Supplement_1/vkag141.1641/8744890)Barrier Stabilization: EQ504 increased IL-22 receptor subunit expression (IL22RA) and decreased the pore-forming tight junction protein claudin-2 (CLDN2), changes not observed with obefazimod.
0 replies
Publicola29 Sep 9, 8:12 PM
$EQ crazy volume close
0 replies